2016 | 2015 | 2014 | 2013
DateTitle 
May 31, 2016Incyte Announces the Launch of the Incyte Charitable Giving Foundation
Foundation to Fund Oncology Patient Support and Resources and Community Partnerships in Delaware WILMINGTON, Del.--(BUSINESS WIRE)--May 31, 2016-- Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company, today announced the launch of the Incyte Charitable Giving Foundation, which will provide charitable donations to publicly-funded 501(c)(3) tax-exempt nonprofit organizations serving the needs of communities in Delaware. ... 
Printer Friendly Version
May 19, 2016Incyte Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Presented at the 2016 ASCO and EHA Annual Meetings
WILMINGTON, Del.--(BUSINESS WIRE)--May 19, 2016-- Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts featuring its clinical development candidates will be presented at the 2016 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings. These conferences will take place from June 3–7, 2016 (ASCO) in Chicago, Illinois and June 9–12, 2016 (EHA) in Copenhagen, Denmark. “The abst... 
Printer Friendly Version
May 18, 2016Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May 18, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 2:00 pm (EDT) in New York; and Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 at 2:00 pm (PDT) / 5:00 pm (EDT) in Rancho Pa... 
Printer Friendly Version
May 09, 2016Incyte First Quarter Financial Results Conference Call and Webcast
WILMINGTON, Del.--(BUSINESS WIRE)--May 9, 2016-- Incyte Corporation (Nasdaq: INCY) today confirms the details for its first quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Monday, May 9, 2016. The conference ID number included in this morning’s press releases was incorrect. The schedule for the press release and conference call/webcast is as follows: ... 
Printer Friendly Version
May 09, 2016Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
Incyte to Accelerate the Expansion of its European Organization to Optimize the Potential of Future Product Launches in Europe ARIAD to Receive $140 Million Upfront Payment, Plus Tiered Royalties on European Sales of Iclusig and Potential Milestones on Future Indications for Iclusig WILMINGTON, Del. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016-- Incyte Corporation (Nasdaq:INCY) and ARIAD Pharmaceuticals... 
Printer Friendly Version
May 09, 2016Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$183 million of 2016 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 59 percent growth over the same period last year. Full year Jakafi net product revenue guidance increased from a range of $800-815 million to a range of $815-830 million. Recent agreements with Lilly and Novartis allow development of ruxolitinib for the treatment of graft versus host disease (GVHD); U.S. pivotal trial expected to b... 
Printer Friendly Version
April 28, 2016Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 28, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11, 2016 at 1:00 pm (PDT) in Las Vegas; and UBS Global Healthcare Conference on Monday, May 23, 2016 at 1:00 pm (EDT) in New York The p... 
Printer Friendly Version
April 15, 2016Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio
Sustained R&D productivity has generated 14 clinical development candidates against 11 discrete molecular targets Diverse immuno-oncology and targeted cancer therapy portfolios comprised of both large and small molecule therapies Live webcast presentation from AACR taking place Sunday, April 17, 2016 at 7:00 p.m. CDT / 8:00 p.m. EDT WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 15, 2016-- Incyte ... 
Printer Friendly Version
April 14, 2016Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 14, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Monday, May 9, 2016. The schedule for the press release and conference call/webcast is as follows:       ... 
Printer Friendly Version
April 06, 2016Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
Pivotal development program for ruxolitinib in GVHD expected to begin in 2016 Novartis agreement amended to include development and commercialization rights for ruxolitinib in GVHD outside of the U.S. WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 6, 2016-- Incyte Corporation (Nasdaq:INCY) today announced it has acquired the rights to develop and commercialize ruxolitinib (Jakafi®), its proprietary JAK1/JAK2 inhibitor, f... 
Printer Friendly Version
March 31, 2016Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics
Pivotal RA-BEACON Study Published in New England Journal of Medicine INDIANAPOLIS, March 31, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe rheumatoid arthritis (RA) — were published today in the New England Journal of Medicine. The study met its pr... 
Printer Friendly Version
March 16, 2016Incyte’s Immuno-oncology and Targeted Therapy Portfolio to be Featured at the AACR Annual Meeting 2016
Ten abstracts selected for presentation from the Company’s GITR agonist, OX40 agonist, LSD1 inhibitor, BRD (BET) inhibitor, PI3Kδ inhibitor and JAK1 inhibitor programs WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 16, 2016-- Incyte Corporation (Nasdaq: INCY) announces that ten abstracts featuring data from its emerging development portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016 in New O... 
Printer Friendly Version
February 29, 2016Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard
February 29, 2016, commemorates International Rare Disease Day Incyte Corporation supports efforts to raise awareness and improve diagnosis and treatment for the nearly 200,000 people in the United States with MPNs, a group of rare blood cancers MPN Heroes® 2016 nominations now open for submission WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 29, 2016-- Incyte Corporation (Nasdaq: INCY) joins the European Organization for Rare... 
Printer Friendly Version
February 16, 2016Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 16, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at 1:20 pm (EST) in Boston; and Barclays Capital Global Healthcare Conference on Wednesday, March 16, 2016 at 9:30 am (EDT) in Miami ... 
Printer Friendly Version
February 11, 2016Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs
$182 million of 2015 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 72 percent growth over the same period last year and $601 million of 2015 full-year net product revenues from Jakafi, representing 68 percent growth over last year 2016 guidance for Jakafi net product revenues in the range of $800 million to $815 million, reflecting expectations for continued growth in underlying demand in myelofi... 
Printer Friendly Version
February 11, 2016Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 11, 2016-- Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a suffic... 
Printer Friendly Version
January 27, 2016Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer (CRC) and high C-reactive protein (CRP) will be stopped early. The decision to stop the sub-study was made after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus reg... 
Printer Friendly Version
January 21, 2016Incyte to Report Fourth Quarter/Year-End Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 21, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter 2015 financial results conference call and webcast for 10:00 a.m. ET on Thursday, February 11, 2016. The schedule for the press release and conference call/webcast is as follows:       ... 
Printer Friendly Version
January 19, 2016Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis
INDIANAPOLIS, Jan. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that Lilly has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA). As a result, Incyte will receive a milestone payment of $35 million from Lilly related to the NDA submission. If baricitinib ... 
Printer Friendly Version
January 11, 2016Incyte Presents Significant Progress in its Development Portfolio
Rapidly advancing portfolio with 13 development molecules being investigated as monotherapy and in combination across multiple indications Two new development molecules—an LSD1 inhibitor and an anti-GITR agonist—added to the portfolio and expected to enter the clinic in first-half of 2016 Rich news flow from pivotal and proof-of-concept programs expected in 2016 Webcast present... 
Printer Friendly Version
January 11, 2016Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 11, 2016-- Incyte Corporation (Nasdaq:INCY) and AstraZeneca (NYSE:AZN) today announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso® (osimertinib). The combination will be assessed as a second-line treatment for patients wit... 
Printer Friendly Version
RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet